OnCo
peoplePerson

Karim Fizazi

Led LATITUDE and PEACE-1, which put abiraterone into first-line metastatic prostate cancer.

Karim Fizazi is one of the most influential prostate cancer trialists of the past two decades, leading LATITUDE (abiraterone in high-risk metastatic hormone-sensitive disease), PEACE-1 (triplet therapy), and studies of radium-223 and PSMA radioligands.

Role
Head of Medical Oncology, Gustave Roussy; Professor, Paris-Saclay
Institution
Gustave Roussy
Specialisms
Prostate cancerGenitourinary oncologyHormone therapyRadioligand therapy
Profiles

Papers

2top
TitleJournalYear
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer (LATITUDE)NEJM2017
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1)Lancet2022

Key papers

1top
rctNew England Journal of Medicine 2021changed practice
VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer

Men with metastatic castration-resistant prostate cancer that has progressed after hormonal therapy and chemotherapy, and whose tumours show PSMA on a PET scan, can now receive lutetium-PSMA, which extends life, controls pain and is usually better tolerated than further chemotherapy. It has established a new treatment class in which a scan decides who gets the matching radioactive drug, and it is now being tested earlier in the disease (PSMAfore, PSMAddition).

Connected

9top

cancers

1
Prostate cancer

targets

1
Androgen receptor

drugs

2
ApprovedSmall-molecule CYP17A1 inhibitor
Abiraterone acetate · Zytiga (generic)
ApprovedTargeted alpha therapy (bone-seeking)
Radium-223 dichloride · Xofigo

institutions

1
Gustave Roussy

trials

3
ALSYMPCALATITUDEPEACE-1

key papers

1
VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer